Understanding how solute carrier proteins affect cell removal and inflammation
Solute carrier proteins in efferocytosis and inflammation
This study is looking at how certain proteins help the body clear away dying cells, which could lead to new treatments for diseases caused by inflammation, and it's for anyone interested in understanding how our bodies manage cell health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11001186 on NIH RePORTER |
What this research studies
This research investigates the role of solute carrier (SLC) proteins in the process of efferocytosis, which is the removal of dying cells from the body. By studying how these proteins interact with apoptotic cells and phagocytes, the research aims to uncover mechanisms that prevent chronic inflammation linked to various diseases. The approach includes laboratory experiments to analyze the function of SLC proteins in cell clearance and their impact on tissue health. Patients may benefit from insights that could lead to new treatments for conditions associated with inflammation and cell turnover.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic inflammatory conditions such as atherosclerosis or inflammatory bowel diseases.
Not a fit: Patients with acute, non-inflammatory conditions may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing chronic inflammatory diseases.
How similar studies have performed: Previous research has shown promising results in understanding the role of efferocytosis in inflammation, suggesting that this approach could yield valuable insights.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ravichandran, Kodi S — Washington University
- Study coordinator: Ravichandran, Kodi S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.